
ECLIPSE 1 Shows Rapid HDV Suppression: Nancy Reau, MD
In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.
Elebsiran plus tobevibart (Vir Biotechnology) suppressed hepatitis delta virus (HDV) in the phase 3 ECLIPSE 1 trial (
An Aggressive Disease, a Dual-Action Regimen
Co-infection with HDV accelerates hepatitis B, raising rates of liver cancer and decompensation, often within 5 years. Reau called it “a very aggressive, very severe disease,” noting that bulevirtide (Hepcludex; Gilead Sciences) is the only approved treatment.
The investigational regimen pairs elebsiran, a small interfering RNA that targets the hepatitis B surface antigen needed for viral replication, with tobevibart, a monoclonal antibody that binds viral particles to block entry into liver cells. This dual approach is expected to deliver potent viral suppression and reduce surface antigen production. The ECLIPSE trial tested the strategy against an untreated comparison. Patients were assigned 2:1 to immediate treatment or a 12-week deferral period that served as the control arm. Active treatment consisted of 2 injections under the skin every 4 weeks for 48 weeks.
Strong Efficacy, Reassuring Safety
All treated patients had at least a 2-log HDV RNA drop. Undetectable virus rose from about 25% at week 12 to about 79% by treatment’s end, and 44% met the composite primary end point of undetectable virus and ALT normalization. No serious adverse events led patients to stop or pause treatment. About 40% had flu-like symptoms, mostly after the first dose, and about 25% had mild injection-site reactions.
“It’s really important when you have something that’s efficacious that is not harmful,” Reau said.
Related to this article








